There are currently 2033 clinical trials in Los Angeles, California looking for participants to engage in research studies. Trials are conducted at various facilities, including Cedars-Sinai Medical Center, USC Norris Comprehensive Cancer Center, Children's Hospital Los Angeles and University of California Los Angeles. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
NCT02074839
Recruiting
The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-120 in advanced hematologic malignancies that harbor an IDH1 mutation. The first portion of the study is a dose escalation phase where cohorts of patients will receive ascending oral doses of AG-120 to determine maximum tolerated dose (MTD) and/or the recommended Phase II dose. The second portion of the study is a dose expansion phase where four cohorts of pati... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/03/2024
Locations: University of California-Los Angeles, Los Angeles, California
Conditions: Relapsed or Refractory Acute Myeloid Leukemia (AML), Untreated AML, Other IDH1-mutated Positive Hematologic Malignancies, Myelodysplastic Syndromes
Register for Updates
Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm
NCT05600894
Recruiting
This phase II trial tests whether decitabine and cedazuridine (ASTX727) in combination with venetoclax work better than ASTX727 alone at decreasing symptoms of bone marrow cancer in patients with chronic myelomonocytic leukemia (CMML), myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) with excess blasts. Blasts are immature blood cells. Decitabine is in a class of medications called hypomethylation agents. It works by helping the bone marrow produce normal blood cells and by killing... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/02/2024
Locations: Los Angeles General Medical Center, Los Angeles, California +1 locations
Conditions: Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts, Myeloproliferative Neoplasm
Register for Updates
Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection
NCT05616221
Recruiting
A phase 2, multi-center, double-blind, randomized, placebo-controlled study to evaluate the safety, phage kinetics, and efficacy of inhaled AP-PA02 administered in subjects with non-cystic fibrosis bronchiectasis and chronic pulmonary Pseudomonas aeruginosa infection.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/02/2024
Locations: Southern California Institute for Respiratory Diseases Cedars-Sinai West Tower, Los Angeles, California
Conditions: Non-cystic Fibrosis Bronchiectasis, Pseudomonas Aeruginosa, Lung Infection
Register for Updates
DILIN - Prospective Study
NCT00345930
Recruiting
The purpose of this study is to identify individuals who have suffered a liver injury arising as an idiosyncratic reaction to a prescription drug or a complementary and alternative medicine. Recently added acute cases enrollment that meets criteria to the protocol. Also added Fibroscans to the protocol that will be completed at baseline and follow-up on chronic subjects.
Gender:
All
Ages:
2 years and above
Trial Updated:
04/02/2024
Locations: University of Southern California, Los Angeles, California
Conditions: Liver Diseases
Register for Updates
Drug-Induced Liver Injury (DILI) Network Retrospective
NCT00360646
Recruiting
The purpose of this study is to establish retrospectively a nationwide registry of patients who have suffered drug-induced liver injury (DILI), and to collect, immortalize, and store serum, DNA, and lymphocytes from these patients. ILIAD will serve as a resource for subsequent mechanistic investigations into the basis of severe idiosyncratic DILI. The primary goal of the ILIAD protocol is to create: (a) a clinical database consisting of individuals who have experienced severe DILI and the releva... Read More
Gender:
All
Ages:
2 years and above
Trial Updated:
04/02/2024
Locations: University of Southen California, Los Angeles, California
Conditions: Drug Induced Liver Injury
Register for Updates
Two Dose Levels of Privigen in Pediatric CIDP
NCT03684018
Recruiting
A randomized, open-label, prospective, multicenter study designed to investigate 2 dose levels in pediatric subjects 2 to ≤ 17 years of age with confirmed or possible CIDP, either previously exposed to IVIG treatment or unexposed to IVIG treatment
Gender:
All
Ages:
Between 2 years and 17 years
Trial Updated:
04/02/2024
Locations: Children's Hospital of Los Angeles, Los Angeles, California
Conditions: Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Register for Updates
Pregistry International Pregnancy Exposure Registry (PIPER)
NCT05352256
Recruiting
The aims of the Pregistry International Pregnancy Exposure Registry (PIPER) are to provide early signals of risk after prenatal exposure to medical products and to define boundaries of safety for medical products. The goal is to assist prescribers and study participants in weighing the potential risks of prenatal treatments on the wellbeing of mother and the unborn offspring. Specifically, the PIPER will estimate the risk of obstetric outcomes (spontaneous abortion, antenatal bleeding, gestatio... Read More
Gender:
Female
Ages:
Between 18 years and 50 years
Trial Updated:
04/01/2024
Locations: Pregistry, Los Angeles, California
Conditions: Pregnancy Related
Register for Updates
Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare
NCT05658575
Recruiting
The purpose of this trial is to investigate the efficacy and safety of dapansutrile (OLT1177®) tablets in subjects with an acute gout flare.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/01/2024
Locations: American Institute of Research, Los Angeles, California
Conditions: Acute Gout Flare, Gout Attack, Gout Flare, Gouty Arthritis, Gout, Arthritis, Joint Pain
Register for Updates
Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer
NCT05401110
Recruiting
The purpose of this study is to examine the combination of osimertinib and carotuximab to assess the safety and find the recommended dose for treatment of advanced EGFR-mutated non-small cell lung cancer (NSCLC). Safety and tolerability will be measured by the number of dose-limiting toxicities, according to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) Version 5, to find the maximum tolerated dose. The secondary objectives include evaluating the rate of objec... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/01/2024
Locations: Cedars-Sinai Cancer at The Angeles Clinic and Research Institute, Los Angeles, California +2 locations
Conditions: Non Small Cell Lung Cancer, Lung Cancer
Register for Updates
Hospital-Based Cluster Trial: Magnetically Controlled Growing Rods Using Distraction Intervals
NCT04058561
Recruiting
A hospital-based cluster stratified randomization control study will be conducted to investigate spinal growth in Early Onset Scoliosis patients between 5 and 9 years of age. Patients must have a major coronal curve measuring over 50 degrees and be undergoing Magnetically Controlled Growing Rod treatment. We will be studying 6-week lengthening intervals compared to 16-week lengthening intervals on spinal growth within 3 years.
Gender:
All
Ages:
Between 5 years and 9 years
Trial Updated:
04/01/2024
Locations: Children's Hospital Los Angeles, Los Angeles, California
Conditions: Early-Onset Scoliosis Deformity of Spine
Register for Updates
LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors
NCT04666688
Recruiting
A Phase 1/2 Open-label, Multi-center Study of the Safety, Pharmacokinetics, and Anti-tumor Activity of LYT-200 Alone and in Combination with Chemotherapy or Tislelizumab in Patients with Metastatic Solid Tumors
Gender:
All
Ages:
18 years and above
Trial Updated:
04/01/2024
Locations: UCLA, Los Angeles, California
Conditions: Metastatic Cancer, Solid Tumor, Colorectal Cancer, Pancreatic Cancer, Urothelial Carcinoma, Head and Neck Cancer
Register for Updates
Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies
NCT05887167
Recruiting
The study is designed to examine the feasibility and safety of collecting autologous hematopoietic stem cells (HSCs) to be combined with CAR T-cell therapy for patients with relapsed/refractory (r/r) hematological disease. The study will evaluate feasibility of collecting the target dose of HSCs from at least 50% of enrolled patients. The study will assess safety based on incidence and severity of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS)... Read More
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
04/01/2024
Locations: Cedars-Sinai Medical Center, Los Angeles, California
Conditions: Hematologic Malignancy, Large B-cell Lymphoma, Acute Lymphoblastic Leukemia, Mantle Cell Lymphoma, Multiple Myeloma, Diffuse Large B Cell Lymphoma
Register for Updates